NCT06048926 2023-09-21Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell CarcinomaThe First Affiliated Hospital with Nanjing Medical UniversityPhase NA Enrolling by invitation30 enrolled